查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1974453

精准肿瘤技术市场分析及预测（至2035年）：依类型、产品类型、服务、技术、应用、最终用户、组件、部署类型及分期划分

Precision Oncology Technologies Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Component, Deployment, Stage
出版日期: | 出版商: Global Insight Services | 英文 305 Pages | 商品交期: 3-5个工作天内

价格
简介目录

精准肿瘤学技术市场预计将从2024年的1,140亿美元成长到2034年的3,021亿美元，复合年增长率约为9%。精准肿瘤学技术市场整合了基因组学、蛋白质组学和生物资讯学，涵盖了针对个别癌症特征量身定制的先进诊断和治疗工具。这些技术能够透过针对独特的基因突变，实现个人化治疗方案并改善患者预后。分子诊断技术的快速发展和癌症研究投入的不断增加正在推动市场成长，凸显了生物标记发现和标靶治疗的发展机会。

精准肿瘤技术市场受到全球关税、地缘政治风险和供应链动态变化的显着影响。为因应贸易摩擦，日本和韩国正在加强国内研发能力，以减少对外国技术的依赖。受地缘政治因素和强有力的医疗政策的双重推动，中国正在加速对本土精准肿瘤解决方案的投资。台湾作为重要的半导体供应商，儘管面临地缘政治风险，但在精准肿瘤技术市场中仍扮演着至关重要的角色。全球精准肿瘤市场正经历强劲成长，这主要得益于技术进步和癌症发生率的上升。预计到2035年，随着区域合作的加强和创新水准的提高，该市场将进一步发展。中东地区的衝突透过能源价格波动间接影响市场，可能对营运成本和供应链稳定性造成衝击。

市场区隔
按类型 诊断试剂、治疗试剂、预后试剂、预测性生物标记
产品 基因检测、伴随诊断、液态生物检体、次世代定序、免疫组织化学、萤光原位杂合反应
服务 咨询、基因组分析、数据解读和临床试验服务
科技 基因定序、聚合酵素链锁反应、微阵列、生物资讯学、奈米技术
适应症 乳癌、肺癌、结肠癌、摄护腺癌、黑色素瘤、白血病
最终用户 医院、诊断检查室、研究机构、製药和生物技术公司
成分 软体、硬体、试剂、试剂盒、耗材
实施表格 本机部署、云端部署、混合式部署
阶段 早期癌症、晚期癌症、復发性癌症

精准癌症治疗技术市场正迅速发展，这主要得益于个人化癌症治疗和基因组分析技术的进步。在诊断领域，基因检测凭藉其识别特定突变并指导标靶治疗的能力，已成为表现最佳的细分市场；其次是液态生物检体技术，该技术为监测疾病进展和治疗反应提供了非侵入性选择。在治疗领域，标靶治疗利用分子层面的洞见开发精准攻击癌细胞的药物，占据主导。免疫疗法，尤其是查核点抑制剂，是成长速度第二快的细分市场，这反映了其对癌症治疗的变革性影响。

人工智慧在精准肿瘤学领域的应用正在不断推进，提高了诊断准确性，并实现了治疗的个人化。人工智慧驱动的数据分析和预测建模平台正成为肿瘤科医生不可或缺的工具。生物技术公司与研究机构之间的合作正在促进创新，并加速新型治疗方法和诊断方法的发展。在改善患者预后和降低成本的潜力驱动下，对精准肿瘤学技术的投资预计将持续成长。

精准肿瘤技术市场的特征是市场份额、定价策略和新产品推出之间存在着动态的相互作用。主要企业正致力于开发创新解决方案，以提高诊断准确性和治疗效果。受技术进步和个人化癌症治疗需求的推动，价格竞争仍然激烈。频繁的新产品发布反映了该行业为满足未被满足的需求和改善患者预后所做的努力。癌症发生率的上升和对精准医疗日益增长的重视正在推动市场发展。

在竞争格局中，主要参与者不断相互参照，以保持竞争优势。监管影响显着，严格的指导方针规范产品开发和核准流程。策略联盟和合作也影响市场格局，增强了研发能力和市场覆盖率。北美和欧洲在监管标准方面处于领先地位，而亚太新兴市场正迅速采用精准肿瘤学技术。人工智慧和基因组学的融合有望彻底改变市场，带来巨大的成长前景。

主要趋势和驱动因素：

精准肿瘤学技术市场正经历强劲成长，这主要得益于几个关键趋势和驱动因素。其中一个关键趋势是基因测序技术的进步，该技术能够更精确地识别癌症突变，而这对于制定个人化治疗方案至关重要。这项技术进步使得精准肿瘤学更加普及且更具成本效益。

另一个趋势是製药公司和科技公司之间合作日益增加。这些伙伴关係正在加速创新诊断工具和治疗方法的研发和商业化。此外，人工智慧和机器学习在肿瘤学领域的应用正在增强预测分析能力，从而改善患者预后并提高治疗效率。

全球癌症发生率的不断攀升推动了市场的发展，也刺激了对更具针对性和更有效治疗方法的需求。各国政府和医疗机构正大力投资精准医疗倡议，并认识到其在革新癌症治疗方面的潜力。以患者为中心的医疗模式的兴起也促进了精准肿瘤学的应用，因为患者和医疗服务提供者都在寻求能够提高生活品质和存活率的个人化治疗方案。这些趋势和驱动因素有望推动精准肿瘤学技术市场实现显着成长，并为相关人员带来盈利的机会。

限制与挑战：

精准肿瘤学技术市场面临许多重大限制与挑战。首先，精准肿瘤学治疗和技术的高成本限制了其可近性，尤其是在低收入地区。这一经济障碍阻碍了技术的广泛应用，也限制了患者获得最先进治疗的机会。其次，癌症基因组学的复杂性和多样性为数据解读和临床决策带来了挑战。这种复杂性需要高度专业的知识，而这些知识并非总是唾手可得。第三，监管障碍和冗长的核准流程会延缓新技术进入市场和创新。这些监管方面的挑战有可能阻碍技术进步的步伐。第四，精准肿瘤学缺乏标准化通讯协定导致治疗结果不一致。这种缺乏标准化的现状使得精准肿瘤学难以融入常规临床实践。最后，由于精准肿瘤学涉及敏感的患者讯息，因此强有力的数据隐私和安​​全措施至关重要。确保遵守资料保护条例仍然是一项重大挑战。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章：细分市场分析

  • 市场规模及预测：依类型
    • 诊断试剂
    • 治疗药物
    • 预后
    • 预测性生物标记
  • 市场规模及预测：依产品划分
    • 基因检测
    • 伴随诊断
    • 液态生物检体
    • 次世代定序
    • 免疫组织化学
    • 萤光原位杂合反应
  • 市场规模及预测：依服务划分
    • 咨询
    • 基因组分析
    • 数据解读
    • 临床试验服务
  • 市场规模及预测：依技术划分
    • 基因定序
    • 聚合酵素链锁反应
    • 微阵列
    • 生物资讯学
    • 奈米科技
  • 市场规模及预测：依应用领域划分
    • 乳癌
    • 肺癌
    • 大肠直肠癌
    • 摄护腺癌
    • 黑色素瘤
    • 白血病
  • 市场规模及预测：依最终用户划分
    • 医院
    • 诊断检查室
    • 研究所
    • 製药公司
    • 生技公司
  • 市场规模及预测：依组件划分
    • 软体
    • 硬体
    • 试剂
    • 成套工具
    • 消耗品
  • 市场规模及预测：依发展状况
    • 本地部署
    • 基于云端的
    • 杂交种
  • 市场规模及预测：依疾病阶段划分
    • 早期癌症
    • 晚期癌症
    • 復发性癌症

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 监管概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • Guardant Health
  • Foundation Medicine
  • Caris Life Sciences
  • Tempus
  • Natera
  • Neo Genomics
  • Personalis
  • Adaptive Biotechnologies
  • Biodesix
  • Invitae
  • Onco Cyte
  • Freenome
  • Grail
  • Helix
  • Bristol Myers Squibb
  • Illumina
  • Strata Oncology
  • Genomic Health
  • Oncocyte Corporation
  • Epic Sciences

第九章 关于我们

简介目录
Product Code: GIS32792

Precision Oncology Technologies Market is anticipated to expand from $114.0 Billion in 2024 to $302.1 Billion by 2034, growing at a CAGR of approximately 9%. The Precision Oncology Technologies Market encompasses advanced diagnostic and therapeutic tools tailored to individual cancer profiles, integrating genomics, proteomics, and bioinformatics. These technologies enable personalized treatment plans, improving patient outcomes by targeting unique genetic mutations. Rapid advancements in molecular diagnostics and increased investment in cancer research are propelling market growth, highlighting opportunities in biomarker discovery and targeted therapies.

The Precision Oncology Technologies Market is significantly influenced by global tariffs, geopolitical risks, and evolving supply chain dynamics. Japan and South Korea are bolstering their domestic capabilities in response to trade tensions, aiming to reduce dependency on foreign technologies. China is accelerating its investment in homegrown precision oncology solutions, driven by both geopolitical factors and a robust healthcare agenda. Taiwan, pivotal in semiconductor supply, faces geopolitical vulnerabilities yet remains indispensable. The global market for precision oncology is witnessing robust growth, driven by technological advancements and rising cancer prevalence. By 2035, the market is expected to evolve with increased regional collaborations and innovation. Middle East conflicts may indirectly affect the market through energy price volatility, influencing operational costs and supply chain stability.

Market Segmentation
TypeDiagnostics, Therapeutics, Prognostics, Predictive Biomarkers
ProductGenetic Tests, Companion Diagnostics, Liquid Biopsy, Next-Generation Sequencing, Immunohistochemistry, Fluorescence In Situ Hybridization
ServicesConsultation, Genomic Profiling, Data Interpretation, Clinical Trial Services
TechnologyGene Sequencing, Polymerase Chain Reaction, Microarray, Bioinformatics, Nanotechnology
ApplicationBreast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia
End UserHospitals, Diagnostic Laboratories, Research Institutes, Pharmaceutical Companies, Biotechnology Firms
ComponentSoftware, Hardware, Reagents, Kits, Consumables
DeploymentOn-Premises, Cloud-Based, Hybrid
StageEarly-Stage Cancer, Advanced-Stage Cancer, Recurrent Cancer

The Precision Oncology Technologies Market is evolving rapidly, propelled by advancements in personalized cancer treatment and genomic profiling. Within the diagnostics segment, genetic testing emerges as the top-performing sub-segment, driven by its ability to identify specific mutations and guide targeted therapies. Liquid biopsy technologies follow closely, offering non-invasive options for monitoring disease progression and treatment response. In the therapeutics segment, targeted therapy leads, leveraging molecular insights to develop drugs that precisely attack cancer cells. Immunotherapy, particularly checkpoint inhibitors, represents the second highest-performing sub-segment, reflecting its transformative impact on cancer care.

The integration of artificial intelligence in precision oncology is gaining momentum, enhancing diagnostic accuracy and treatment personalization. AI-driven platforms for data analysis and predictive modeling are becoming indispensable tools for oncologists. Collaboration between biotech firms and research institutions is fostering innovation, accelerating the development of novel therapeutics and diagnostic approaches. Investment in precision oncology technologies is expected to continue, driven by the promise of improved patient outcomes and reduced healthcare costs.

The Precision Oncology Technologies Market is characterized by a dynamic interplay of market share, pricing strategies, and new product introductions. Leading companies are focusing on innovative solutions that enhance diagnostic accuracy and treatment efficacy. Pricing remains competitive, influenced by technological advancements and the demand for personalized cancer therapies. New product launches are frequent, reflecting the sector's commitment to addressing unmet medical needs and improving patient outcomes. The market is buoyed by the increasing prevalence of cancer and the growing emphasis on precision medicine.

In terms of competition, key players are continuously benchmarking against each other to maintain a competitive edge. Regulatory influences are significant, with stringent guidelines shaping product development and approval processes. The market landscape is further influenced by strategic alliances and collaborations, enhancing research capabilities and market reach. North America and Europe are at the forefront of regulatory standards, while emerging markets in Asia-Pacific are rapidly adopting precision oncology technologies. The integration of artificial intelligence and genomics is poised to revolutionize the market, offering substantial growth prospects.

Geographical Overview:

The Precision Oncology Technologies Market is witnessing a dynamic expansion across various regions, each contributing uniquely to its growth. North America leads, driven by advanced healthcare infrastructure and substantial investments in precision medicine research. The presence of major biotech firms accelerates technological advancements, enhancing the region's market dominance. In Europe, robust government initiatives supporting personalized medicine and a strong focus on research and development are propelling market growth.

The region's emphasis on regulatory frameworks also fosters a conducive environment for innovation. In the Asia Pacific, the market is burgeoning, fueled by increasing cancer prevalence and rising healthcare expenditures. Countries like China and India are emerging as significant players, driven by technological advancements and growing awareness of precision oncology. Latin America and the Middle East & Africa are gradually recognizing the potential of precision oncology technologies. These regions are witnessing increased investments and collaborations, paving the way for future growth and innovation.

Recent Developments:

The Precision Oncology Technologies Market has experienced notable developments in recent months. Roche announced a strategic partnership with Illumina to enhance its precision oncology offerings, focusing on integrating genomic sequencing technologies to optimize cancer treatment strategies. This collaboration aims to accelerate the development of personalized cancer therapies.

In another significant move, Thermo Fisher Scientific completed the acquisition of a leading genomic diagnostics company, augmenting its capabilities in precision oncology. This acquisition is expected to bolster Thermo Fisher's portfolio, enabling more comprehensive diagnostic solutions for oncology patients.

Meanwhile, Guardant Health launched an innovative liquid biopsy test designed to provide real-time insights into tumor genetics, offering a less invasive alternative to traditional biopsies. This product launch is anticipated to revolutionize cancer diagnostics by enhancing the precision of treatment decisions.

On the regulatory front, the U.S. FDA has introduced new guidelines to expedite the approval process for precision oncology drugs, aiming to bring innovative treatments to market more swiftly. This regulatory shift is likely to stimulate further advancements in the sector.

Financially, the precision oncology market has attracted substantial investment, with venture capital firms injecting significant funds into startups specializing in AI-driven oncology solutions. This influx of capital underscores the market's potential and the growing interest in leveraging technology to transform cancer care.

Key Trends and Drivers:

The Precision Oncology Technologies Market is experiencing robust expansion, fueled by several key trends and drivers. A significant trend is the advancement of genomic sequencing technologies, enabling more precise identification of cancer mutations, which is crucial for personalized treatment plans. This technological progress is making precision oncology more accessible and cost-effective.

Another trend is the growing collaboration between pharmaceutical companies and technology firms. These partnerships are accelerating the development and commercialization of innovative diagnostic tools and treatments. Furthermore, the integration of artificial intelligence and machine learning in oncology is enhancing predictive analytics, leading to improved patient outcomes and treatment efficiency.

Drivers of this market include the increasing prevalence of cancer worldwide, prompting a demand for more targeted and effective therapies. Governments and healthcare institutions are investing heavily in precision medicine initiatives, recognizing their potential to revolutionize cancer treatment. The rise of patient-centric care models is also driving the adoption of precision oncology, as patients and healthcare providers seek tailored treatment options that improve quality of life and survival rates. With these trends and drivers, the Precision Oncology Technologies Market is poised for substantial growth, offering lucrative opportunities for stakeholders.

Restraints and Challenges:

The Precision Oncology Technologies Market is confronted with several significant restraints and challenges. Firstly, the high cost of precision oncology treatments and technologies restricts their accessibility, particularly in low-income regions. This financial barrier hinders widespread adoption and limits patient access to cutting-edge therapies. Secondly, the complexity and variability of cancer genomics present challenges in data interpretation and clinical decision-making. This complexity demands highly specialized expertise, which is not always readily available. Thirdly, regulatory hurdles and lengthy approval processes for new technologies can delay market entry and innovation. These regulatory challenges can stifle the pace of technological advancement. Fourthly, there is a lack of standardized protocols for precision oncology, leading to inconsistencies in treatment outcomes. This absence of standardization complicates the integration of precision oncology into routine clinical practice. Lastly, the need for robust data privacy and security measures is critical, as sensitive patient information is integral to precision oncology. Ensuring compliance with data protection regulations remains a formidable challenge.

Key Companies:

Guardant Health, Foundation Medicine, Caris Life Sciences, Tempus, Natera, Neo Genomics, Personalis, Adaptive Biotechnologies, Biodesix, Invitae, Onco Cyte, Freenome, Grail, Helix, Bristol Myers Squibb, Illumina, Strata Oncology, Genomic Health, Oncocyte Corporation, Epic Sciences

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Component
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Diagnostics
    • 4.1.2 Therapeutics
    • 4.1.3 Prognostics
    • 4.1.4 Predictive Biomarkers
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Genetic Tests
    • 4.2.2 Companion Diagnostics
    • 4.2.3 Liquid Biopsy
    • 4.2.4 Next-Generation Sequencing
    • 4.2.5 Immunohistochemistry
    • 4.2.6 Fluorescence In Situ Hybridization
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Consultation
    • 4.3.2 Genomic Profiling
    • 4.3.3 Data Interpretation
    • 4.3.4 Clinical Trial Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Gene Sequencing
    • 4.4.2 Polymerase Chain Reaction
    • 4.4.3 Microarray
    • 4.4.4 Bioinformatics
    • 4.4.5 Nanotechnology
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Breast Cancer
    • 4.5.2 Lung Cancer
    • 4.5.3 Colorectal Cancer
    • 4.5.4 Prostate Cancer
    • 4.5.5 Melanoma
    • 4.5.6 Leukemia
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Diagnostic Laboratories
    • 4.6.3 Research Institutes
    • 4.6.4 Pharmaceutical Companies
    • 4.6.5 Biotechnology Firms
  • 4.7 Market Size & Forecast by Component (2020-2035)
    • 4.7.1 Software
    • 4.7.2 Hardware
    • 4.7.3 Reagents
    • 4.7.4 Kits
    • 4.7.5 Consumables
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 On-Premises
    • 4.8.2 Cloud-Based
    • 4.8.3 Hybrid
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Early-Stage Cancer
    • 4.9.2 Advanced-Stage Cancer
    • 4.9.3 Recurrent Cancer

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Component
      • 5.2.1.8 Deployment
      • 5.2.1.9 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Component
      • 5.2.2.8 Deployment
      • 5.2.2.9 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Component
      • 5.2.3.8 Deployment
      • 5.2.3.9 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Component
      • 5.3.1.8 Deployment
      • 5.3.1.9 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Component
      • 5.3.2.8 Deployment
      • 5.3.2.9 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Component
      • 5.3.3.8 Deployment
      • 5.3.3.9 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Component
      • 5.4.1.8 Deployment
      • 5.4.1.9 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Component
      • 5.4.2.8 Deployment
      • 5.4.2.9 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Component
      • 5.4.3.8 Deployment
      • 5.4.3.9 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Component
      • 5.4.4.8 Deployment
      • 5.4.4.9 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Component
      • 5.4.5.8 Deployment
      • 5.4.5.9 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Component
      • 5.4.6.8 Deployment
      • 5.4.6.9 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Component
      • 5.4.7.8 Deployment
      • 5.4.7.9 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Component
      • 5.5.1.8 Deployment
      • 5.5.1.9 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Component
      • 5.5.2.8 Deployment
      • 5.5.2.9 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Component
      • 5.5.3.8 Deployment
      • 5.5.3.9 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Component
      • 5.5.4.8 Deployment
      • 5.5.4.9 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Component
      • 5.5.5.8 Deployment
      • 5.5.5.9 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Component
      • 5.5.6.8 Deployment
      • 5.5.6.9 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Component
      • 5.6.1.8 Deployment
      • 5.6.1.9 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Component
      • 5.6.2.8 Deployment
      • 5.6.2.9 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Component
      • 5.6.3.8 Deployment
      • 5.6.3.9 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Component
      • 5.6.4.8 Deployment
      • 5.6.4.9 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Component
      • 5.6.5.8 Deployment
      • 5.6.5.9 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Guardant Health
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Foundation Medicine
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Caris Life Sciences
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Tempus
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Natera
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Neo Genomics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Personalis
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Adaptive Biotechnologies
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Biodesix
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Invitae
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Onco Cyte
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Freenome
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Grail
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Helix
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Bristol Myers Squibb
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Illumina
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Strata Oncology
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Genomic Health
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Oncocyte Corporation
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Epic Sciences
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us